Brachytherapy for rhabdomyosarcoma: Survey of international clinical practice and development of guidelines

Brachytherapy can be a highly effective treatment with very limited morbidity for some carefully selected children with rhabdomyosarcoma (RMS). However, access may be limited by the need for highly specialized experienced teams that are needed to deliver the service [1]. RMS is the most common soft tissue sarcoma of childhood, accounting for around 3.5  % of all malignant diseases in children [2,3]. RMS derives from embryonal mesenchyme and can arise at almost any anatomical site. Current multimodal treatment strategies including chemotherapy, surgery, and radiotherapy achieve an overall 5-year survival rate of 80 % [4].

Source: Radiotherapy and Oncology - April 6, 2024 Category: Radiology Authors: Raquel D ávila Fajardo, Giovanni Scarzello, Mark N Gaze, Tom Boterberg, Alison Cameron, Joerg Fuchs, Florent Guérin, Peter Hoskin, Matthew J Krasin, Petra Kroon, Henriette Magelssen, Claes Mercke, Johannes H.M. Merks, Frank Paulsen, Pascal Pommier, Moni Tags: Original Article Source Type: research